A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants
Completed · Phase 1 · NCT06722417
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $384,552
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 16
About the trial
- Sponsor
- AbbVie
- Tested
- Icalcaprant (drug)
- Dates
- Started 2024-11-26; completion 2025-01-17
- Results posted
- Not yet
This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.
From ClinicalTrials.gov, last updated 2025-01-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $384,552 in research payments for this study in 2025 (14 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Anaheim Clinical Trials LLC $384,552
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.